Recently, the biopharmaceutical industry in the Guangdong Hong Kong Macao Greater Bay Area has achieved a good start. The official WeChat official account of Guangdong Provincial Food and Drug Administration announced yesterday that the State Food and Drug Administration has recently approved the listing of three types of Class 1 innovative drugs in the region, namely, Stadumumab injection, Racacizumab for injection, and Natltamivir Phosphate Capsules, which marks that the Great Bay Area has taken a solid step in the field of biomedical innovation, and the number of new drugs launched in the world has reached a record high.

The approval of innovative drugs demonstrates the initial results of the Greater Bay Area's sustained investment in the field of biomedicine in recent years. It is reported that the world's first ultra long acting PCSK9 monoclonal antibody developed by Guangdong Hengrui Pharmaceutical Co., Ltd. is used to treat hypercholesterolemia, breaking through the bottleneck of short dosing intervals of existing PCSK9 monoclonal antibodies, with more flexible dosing frequency and better patient compliance. It can also be used as a monotherapy for adult patients with non familial hypercholesterolemia and mixed dyslipidemia; The hepatitis C virus NS5A inhibitor developed by Guangdong Dongyangguang Pharmaceutical Co., Ltd. is suitable for use in combination with esomeprazole tablets to treat adult chronic hepatitis C virus (HCV) infections of genotype 1, 2, 3, and 6 that have been previously treated or treated with interferon. It can be combined or not with compensatory liver cirrhosis. This drug is the first to cover the population of compensatory liver cirrhosis patients and expands the applicable population; The world's first recombinant monoclonal antibody against tetanus toxin developed by Zhuhai Tainuo Mabo Pharmaceutical Co., Ltd. As a new generation of "tetanus vaccine", this product is a passive immunization preparation used for emergency prevention of adult tetanus.